ORBIMED ADVISORS LLC 13D and 13G filings for Jounce Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 4:30 pm Sale | 2022-12-31 | 13G | JOUNCE THERAPEUTICS INC. JNCE | ORBIMED ADVISORS LLC | 0 0.000% | -2,200,200 (Position Closed) | Filing |
| 2022-02-11 4:27 pm Purchase | 2021-12-31 | 13G | JOUNCE THERAPEUTICS INC. JNCE | ORBIMED ADVISORS LLC | 2,200,200 4.300% | 2,200,200 (New Position) | Filing |